Compare FRO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRO | TGTX |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.9B |
| IPO Year | 1995 | 2008 |
| Metric | FRO | TGTX |
|---|---|---|
| Price | $37.07 | $35.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $37.67 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 05-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | N/A | $49.08 |
| Revenue Next Year | N/A | $26.69 |
| P/E Ratio | $34.05 | ★ $12.22 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.25 | $25.37 |
| 52 Week High | $39.89 | $40.99 |
| Indicator | FRO | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 58.82 |
| Support Level | $33.61 | $32.95 |
| Resistance Level | $38.16 | $37.92 |
| Average True Range (ATR) | 1.39 | 1.37 |
| MACD | 0.08 | -0.30 |
| Stochastic Oscillator | 78.83 | 54.76 |
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.